Similarly, patients with KRAS-mutant/KEAP1-mutant NSCLC had lower PFS and OS (1.8 and 4.8 months, respectively) than those with KRAS-mutant/KEAP1-wildtype variety (4.6 and 18.4 months, respectively; HR 2.05, 95% CI 1.63–2.59, p < 0.0001) (67). The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.